No Limit Stocks carries an inclusive analysis of (NASDAQ:GERN), (NASDAQ:ALXN), (NASDAQ:EXEL), (NASDAQ:CLSN)
Pompano Beach, FL -- (SBWIRE) -- 01/03/2013 -- No Limit Stocks - NOLIMITSTOCKS.com covers all the latest on up and coming stocks in the market. No limit Stocks team contain experts that study and analyzes the stock market and help individuals break through the limits and make them better & more successful investors.
Geron Corporation (NASDAQ:GERN) remained a bull for the day as itreported the upward momentum of 5.67% and closed at $1.49 after gaining total volume of 2.20 million shares.
GERN has the total of 130.76million outstanding shares and its total market capitalization is $194.83 million.
Company’s year to date performance remained quite optimistic with the gain of 5.67% while in last 6 months it declined-15.82%. During Last three months company reported a downward momentum of -10.24%.
Geron Corporation (NASDAQ:GERN) reported that on Thursday, January 10at 1:00 p.m. Pacific Time the President, Chief Executive Officer and M.D of the company, John A. Scarlettwill be presenting an overview of the Geron Corporation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.
Will GERN Continue To Move Higher? Find Out Here
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) ended its day with the gaining stream with the rise of 6.73% and closed at the price of $100.05after opening at $96.15. Stock traded during its last trading session with the total traded volume of 2.00 million shares as compared to its average volume of 1.11 million shares.
During the previous session company’s minimum price was $96.01 while it touched its highest price for the day at $100.06. ALXN’s beta value stands at 0.59 points.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) reported that on Monday, January 7, 2013 at 9:00 a.m. Pacific time and 12:00 p.m. Eastern time the Chief Executive Officer of the company,Dr. Leonard Bell will presentat the JP Morgan 31st Annual Healthcare Conferencein San Francisco
Should ALXN a Buy or Sell Now? Find Out Here
Exelixis, Inc. (NASDAQ:EXEL) percentage change climbed 5.69% to close at $4.83 with the total traded volume of 2.65 million shares as compare to average volume of 2.84 million.
Company’s year to date performance remained quite optimistic with the gain of 5.69% while in last 6 months it slipped -19.77%.
Its market capitalization is $886.77 million. Its beta value stands at 1.98 times. EXEL’s shares were trading within the range of $4.58 - $4.84 while its opening price was $4.70.
For How Long EXEL’s Gloss will Attract Investors? Find out via this report
Celsion Corporation (NASDAQ:CLSN) reported the rise of 1.22% to close at $8.29 with the overall traded volume of 2.20 million shares. Its market capitalization was 290.26 million. Its beta value stands at 1.20 times and earning per share was $-0.76.
Celsion Corporation (NASDAQ:CLSN) has the total of 35.01 million outstanding shares. During last trade company’s minimum price was $8.13 while it touched highest price of $8.58.
Why Should Investors Buy CLSN After The Recent Gain? Just Go Here and Find Out
About No Limit Stocks
NOLIMITSTOCKS.com is made up of a team of professional analyst that possess over 30 years of expert, stock market experience. Our goal is to research thousands of companies and provide investors with the latest insights in the market with stocks that can make explosive profits. We study the hottest companies so you don't have to!
Our newsletter is always free to Join and offers a variety of useful investors tools that will help you break the limits! There will be no regrets!
The assembled information disseminated by nolimitstocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. nolimitstocks.com does expect that investors will buy and sell securities based on information assembled and presented in nolimitstocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)